The clinical pharmacist systematically analyzed the correlation between drug-induced renal injury caused by long-term administration of tacrolimus and tenofovir dipivoxil fumarate in a patient with hepatitis B virus infection after liver transplantation. In combination with relevant guidelines and literature reports, the clinical pharmacist suggested that doctors replace the patient's medication with sirolimus and tenofovir alafenamide fumarate, and give the patient medication education and supervision. After relevant treatment, the patient's renal function gradually returned to normal, and the disease was controlled and discharged smoothly. Clinical pharmacists use their professional knowledge to provide medication advice to patients with drug-induced diseases and carry out pharmaceutical services, which will help improve the safety and effectiveness of long-term medication for patients.

1. 中华医学会器官移植学分会.中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J].器官移植, 2021, 12(1): 8-28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.

2. 陈文倩, 张雷, 张弋, 等.实体器官移植他克莫司个体化治疗专家共识[J].中国医院用药评价与分析, 2021, 21(12): 1409-1424. [Chen WQ, Zhang L, Zhang Y, et al. Expert consensus on individual treatment of tacrolimusin solid organ transplantation[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2021, 21(12): 1409-1424.]DOI: 10.14009/j.issn.1672-2124. 2021.12.001.

3. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4): c179-c184. DOI: 10.1159/000339789.

4. 葛均波, 徐永健, 王辰, 主编.内科学(第9版)[M].北京: 人民卫生出版社, 2018: 511-517.

5. Huang WC, Wang MT, Lai TS, et al. Nephrotoxins and acute kidney injury-The consensus of the Taiwan acute kidney injury Task Force[J]. J Formos Med Assoc, 2022, 121(5): 886-895. DOI: 10.1016/j.jfma.2021.12.007.

6. lavecchia L, Cereza García G, Sabaté Gallego M, et al. Drug-related acute renal failure in hospitalised patients[J].Nefrologia, 2015, 35(6): 523-532. DOI: 10.1016/j.nefro. 2015.09.007.

7. Lee J, Park JY, Yang SJ, et al. Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients[J]. J Viral Hepat, 2020, 27(8): 818-825. DOI: 10.1111/jvh.13291.

8. 苗芸, 于立新, 邓文锋, 等.肾移植术后常规免疫抑制方案下发生他克莫司肾毒性的影响因素[J].中华器官移植杂志, 2011, (9): 523-526. [Miao Y, Yu LX, Deng WF, et al. Risk factors for standard Tac-related nephrotoxicity in renaltransplant recipients[J]. Chinese Journal of Organ Transplantation, 2011(9): 523-526.] DOI: 10.3760/cma.j.issrL0254-1785.2011.09.004.

9. 汤汝佳, 郭晓东, 熊璐.肝移植术后他克莫司肾毒性1例报道及文献复习[J].现代生物医学进展, 2012, 12(35): 6881-6883. [Tang RJ, Guo XD, Xiong L. A case report and literatur e review of tacrolimus renal toxicity after liver transplantation[J]. Progress in Modern Biomedicine, 2012, 12(35): 6881-6883.] DOI: 10.13241/j.cnki.pmb.2012.35.044.

10.鞠卫强, 何晓顺, 王东平, 等.西罗莫司在肝移植术后钙调素类抑制剂相关肾损病人中的应用[J].中华肝胆外科杂志, 2010, 16(2): 112-114. [Ju WQ, He XS, Wang DP, et al. Sirolimus conversion in liver transplant recipients with calcineurin inhibitor-related renal insufficiency after liver transplantation[J]. Chinese Journal of Hepatobiliary Surgery, 2010, 16(2): 112-114.] DOI: 10.3760/ema.j.issn.1007-8118.2010.02.011.

11.中国医师协会器官移植医师分会肝移植学组, 中华医学会器官移植学分会肝移植学组.西罗莫司在肝癌肝移植中应用的中国专家共识(2020版)[J].中华消化外科杂志, 2020, 19(6): 589-597. DOI: 10.3760/cma.j.cn115610-20200513-00349.

12.Ye Q, Ling S, Jiang G, et al. Sirolimus-based immunosuppression improves the prognosis of liver transplantation recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria[J]. Eur J Surg Oncol, 2021, 47(10): 2533-2542. DOI: 10.1016/j.ejso.2021.04.001.

13.Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Liver Transpl, 2008, 14(5): 633-638. DOI: 10.1002/lt.21420.

14.Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial[J]. Transplantation, 2016, 100(1): 116-125. DOI: 10.1097/TP.0000000000000965.

15.管昊晨, 袁伟杰.核苷(酸)类似物长期治疗对慢性乙型肝炎患者肾脏的影响及其机制探讨[J].中华医学杂志, 2020, 100(35): 2797-2800. [Guan HC, Yuan WJ. Effect of long-term treatment with nucleos(t)ide analogues on kidney of patients with chronic hepatitis B and its mechanism[J]. National Medical Journal of China, 2020, 100(35): 2797-2800.] DOI: 10.3760/cma.j.cn112137-20200408-01119.

16.中华医学会感染病学分会, 中华医学会肝病学分会.慢性乙型肝炎防治指南(2019 年版)[J].中华传染病杂志, 2019, 37(12): 711-736. DOI: 10.3760/cma.j.issn.1000-6680.2019.12.003.

17.Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68(4): 672-681. DOI: 10.1016/j.jhep.2017.11.039.

18.Sripongpun P, Mannalithara A, Kwo PY, et al. Potential benefits of switching liver transplant recipients to tenofbvir alafenamide prophylaxis[J]. Clin astroenterol Hepatol, 2020, 18(3): 747-749. DOI: 10.1016/j.cgh.2019.05.057.

19.Kaneko S, Kurosaki M, Tamaki N, et al. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate[J].J Gastroenterol Hepatol, 2019, 34(11): 2004-2010. DOI: 10.1111/jgh.14686.

20.Rashidi-Alavijeh J, Straub K, Achterfeld A, et al. Safety and efficacy of tenofovir alafenamide in liver transplant recipients: a single center experience[J]. Transpl Infect Dis, 2021, 23(3): e13522. DOI: 10.1111/tid.13522.

21.陈积, 唐茂华, 王乡, 等.富马酸丙酚替诺福韦与富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎的临床疗效及安全性[J].沈阳医学院学报, 2022, 24(2): 140-142. [Chen J, Tang MH, Wang X, et al. Clinical efficacy and safety of tenofovir alafenamide fumarate and tenofovir disoproxil fumarate in the treatment of chronic hepatitis B[J]. Journal of Shenyang Medical College, 2022, 24(2): 140-142.] DOI: 10.16753/j.cnki.1008-2344.2022.02.007.

22.陈依雨, 方楚璇, 刘滔滔, 等.基于openFDA的西罗莫司和依维莫司不良反应信号挖掘与分析[J].药物流行病学杂志, 2022, 31(6): 381-387. [Chen YY, Fang CX, Liu TT, et al. Mining and analysis of the adverse drug reactions induced by sirolimus and everolimus based on OpenFDA[J]. Chinese Journal of Pharmacoepidemioly, 2022, 31(6): 381-387.] DOI: 10.19960/j.cnki.issn1005-0698.2022. 06.004.